Alzheimer’s Community Prepares To Challenge CMS PET Proposal
This article was originally published in The Gray Sheet
Executive Summary
Alzheimer’s researchers are planning to join with industry in a unified response to a Medicare coverage proposal that would, in their view, disastrously constrain use of positron emission tomography, and imaging agents like Eli Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.
You may also be interested in...
Trial-Only Medicare Coverage Proposed For PET Alzheimer’s Scans
Beta amyloid positron emission tomography scans to help diagnose dementia would only be covered by Medicare as part of a clinical trial under a proposed national coverage decision. Eli Lilly requested broader coverage for its Amyvid PET imaging agent.
Bending To Overwhelming Feedback, CMS Softens Stance On PET For Solid Tumors
In a final decision memo released June 11, the Medicare agency provides national coverage for three post-cancer-treatment PET scans. The original coverage proposal would have allowed only one.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.